Clinical Study
A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
Table 3
Glycemic excursion parameters at the end of treatment with continuous subcutaneous insulin infusion (group A) or basal insulin glargine plus oral hyperglycemic agent (group B).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
†Data are mean (standard deviation) unless otherwise stated. ‡Median (range) AUC > 7.8 mmol/L, area under the curve above 7.8 mmol/L; AUC < 3.9 mmol/L, area under the curve below 3.9 mmol/L. MBG: mean blood glucose; SDBG: standard deviation of blood glucose; MAGE: mean amplitude of glycemic excursions; FGE: frequency of glycemic excursion; MODD: mean of daily differences. |